http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103764169-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 |
| filingDate | 2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103764169-B |
| titleOfInvention | For the perfluorochemical of non-viral transfer nucleic acid |
| abstract | Compound the present invention relates to lead to formula (I)：The compound of A B C (F, G ') D E F G A ' or formula (II) structure：A‑B‑C(F′,G′)‑D‑B‑E‑F‑G‑A′(Ⅱ),It is characterized in that,Wherein A is at least one selected from perfluocarbon (PFC),Molecule in the group of perfluorinate silicon compound and/or further perfluorochemical,B is at least one physics,The predetermined breakaway poing of chemistry or enzyme scissionable bond form,C does not exist or is at least one connection molecule,D does not exist or is at least one spacer molecule,E is at least one selected from core base,Nucleosides,Nucleotides,Oligonucleotides,Nucleic acid,The core base of modification,The nucleosides of modification,The nucleotides of modification,The oligonucleotides of modification,The nucleic acid of modification,Peptide nucleic acid monomer,Molecule in the group of peptide nucleic acid oligomer and peptide nucleic acid or other nucleic acid analogs,‑F,F ' does not exist or is at least one part,‑G,G ' does not exist or is at least one mark molecule,A ' does not exist or is the implication of A,And wherein compound i),ii),iii),iv),v),Vi except).The invention further relates to the purposes that the compound is used for the non-viral purposes being transferred in cell of molecule E, the pharmaceutical composition containing the compound, and described pharmaceutical composition. |
| priorityDate | 2011-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 275.